Investment Rating - The report maintains a rating of "stronger than the market" for the defense industry [4]. Core Viewpoints - The report highlights that aerospace has been designated as an emerging pillar industry for the first time in the 2026 government work report, alongside integrated circuits, biomedicine, and the low-altitude economy, indicating increased attention and investment potential in these sectors [3][45]. - Significant investments in satellite internet and other major projects are anticipated, with scales reaching hundreds of billions or even trillions [3][46]. - The report emphasizes the importance of domestic rocket development, the overseas SpaceX/Tesla supply chain, and technological innovations in the satellite industry as key areas for investment [3][51][52]. Summary by Sections Domestic Rockets - Three core logic points are presented: 1. Macro: Strong launch capacity is a strategic high ground for major powers, similar to GPUs [4][51]. 2. Mid-level: The objective gap establishes a logic for rocket quantity inflation, with a significant increase expected within five years [4][51]. 3. Micro: The listing and financing of rocket companies will drive capacity expansion across the entire industry chain, achieving a dual boost in PE and EPS [4][51]. - Recommended companies include Feiwo Technology, Western Materials, Aerospace Power, and others [4][51]. SpaceX/Tesla Supply Chain - The report notes that overseas commercial aerospace industries, represented by SpaceX, are progressing rapidly in rocket launches, Starlink deployment, and photovoltaic construction [4][52]. - Companies to watch include Lens Technology, Yujing Co., and others [4][52]. Technological Innovations in the Satellite Industry - The report indicates that new technologies such as flexible solar wings and low-cost commercial satellites are entering a rapid development phase, with new suppliers emerging [4][56]. - Suggested companies for investment include Aerospace Electronics, Geberit, and others [4][56]. Military Industry Focus - The report suggests focusing on commercial engines, nuclear fusion, and drones, highlighting companies like Aerospace Technology, and others [4][57][58]. - The report also notes ongoing geopolitical tensions that may catalyze demand in missile, unmanned, and military trade sectors [4][58].

Macro and Strategy Research - The US ISM manufacturing PMI slightly declined in February but remains in the expansion range, with new orders and output indices still robust. However, the price index jumped, indicating inflationary pressures [2][3] - The ADP report shows that private sector job creation in the US reached a new high since the end of last year, supporting the view of a stable labor market despite job growth being limited to a few sectors [2] - In Europe, inflation data in February was driven by rising service prices, with expectations that the European Central Bank will maintain its policy rates unchanged throughout the year [3] Fixed Income Research - In February, the central bank's liquidity net injection exceeded 800 billion yuan, with a significant amount of reverse repos conducted. The money market saw a slight increase in prices before the Spring Festival, but the fluctuations were lower than in previous years [5][6] - The issuance of interest rate bonds in February totaled 2.5 trillion yuan, showing a slight decrease year-on-year, with net financing of approximately 1.3 trillion yuan [6][7] - The bond market is expected to remain in a strong oscillation pattern, with inflation and policy changes being key factors that could influence market dynamics [9] Industry Research - The 2026 government work report highlights the brain-computer interface as a new pillar industry, indicating a strategic focus on emerging sectors such as biomedicine [10][12] - Notable industry developments include the approval of new drugs by companies like China Biologic Products and Innovent Biologics, reflecting ongoing innovation in the pharmaceutical sector [11] - The SW biomedicine sector's valuation remains high, with a TTM P/E ratio of 48.07, indicating significant investor interest despite recent market declines [11][12]

Policy Dynamics - The 2026 government work report emphasizes the establishment of a risk-sharing mechanism for future industries, particularly focusing on quantum technology, future energy, embodied intelligence, brain-computer interfaces, and 6G [5][6] - The report indicates a shift towards a collaborative model where state-owned enterprises lead and social capital follows, with national funds covering initial R&D losses [5] Quantum Technology - Huawei launched the "Galaxy AI Network Flux Integration Solution" at the 2026 World Mobile Communication Conference, significantly lowering the deployment costs and barriers for quantum encryption technology [7][9] - French quantum computing company Pasqal plans to go public via SPAC on NASDAQ, with a valuation of $2 billion, showcasing the commercial competitiveness of the neutral atom approach [10][11] - A Chinese research team achieved breakthroughs in solid-state quantum light sources, developing a high-efficiency dual-photon emitter, which aids in the domestic production of quantum computers [12] Hydrogen and Nuclear Fusion - The Baowu Clean Energy (Yangjiang) green hydrogen industrial park has officially launched, exploring the direct hydrogen production model from offshore wind power with a total investment of 11 billion yuan [14][15] - The "14th Five-Year Plan" outlines a trillion-level future industry layout, emphasizing nuclear fusion and green hydrogen alongside major energy projects [16] Brain-Computer Interfaces - Science Corporation has accelerated the commercialization of its PRIMA retinal implant system, completing a $230 million Series C funding round to enhance production capacity and develop new technologies [18][19] Embodied Intelligence - Honor has released its first humanoid robot and "robot phone," which features innovative design and capabilities for physical perception and execution [21][22] 6G and Commercial Space - The global communication industry is transitioning from 5G-A to 6G, with companies like Huawei and ZTE promoting the commercial use of the U6GHz frequency band [23][26] - SpaceX plans to launch 1,200 second-generation "Starlink" satellites by the end of 2027, aiming for global seamless coverage, which aligns with the 6G vision of comprehensive connectivity [30][31] Future Industry Catalysts - A table summarizing key catalytic events for six future industries in 2026 is provided, highlighting important milestones and conferences [33]

Domestic Developments - The Ministry of Science and Technology issued guidelines for the development of a comprehensive technology insurance system, aiming to support high-level technological self-reliance and innovation through 20 measures[9] - The National Development and Reform Commission held a meeting focusing on expanding domestic demand and stabilizing investment, with a commitment to accelerate targeted policies for private enterprises[10] - A tax data report indicated that by 2025, over 80% of provinces in China will see positive growth in inter-provincial sales, reflecting the progress in building a unified national market[12] International Developments - The U.S. and Israel launched strikes against Iran, leading to significant geopolitical tensions and fluctuations in asset prices, including a rise in oil prices above $80 per barrel[16] - In February, the U.S. manufacturing PMI remained in expansion territory at 52.4, but the input price index surged to a near four-year high of 70.5, indicating rising inflationary pressures[18] - The Eurozone's February CPI rose by 1.9% year-on-year, exceeding expectations, driven by increased service prices, particularly in Italy, which saw a 6.1% rise in restaurant and accommodation costs[21] Market Trends - Brent crude oil prices increased by 15.77% week-on-week, while iron ore prices rose by 0.72%, indicating upward pressure in commodity markets[25] - Real estate sales surged by 63.37% week-on-week, reflecting a strong recovery in the housing market[25] - The DXI index for storage DRAM prices increased by 2.15% week-on-week, suggesting a positive trend in emerging industries[33]

Company and Industry Summary Company: 壹网壹创 (Yiwang Yichuang) Key Points 1. **Collaboration with 联世传奇 (Lianshi Legend) to Capture AI Agent Market** The merger is expected to be completed in the second half of 2026. The collaboration will focus on four areas: integration of AI investment capabilities, leveraging a multi-billion yuan investment scale for better commercial opportunities, enhancing GEO co-creation to capture the AI Agent market, and mutual support due to low overlap in existing customer bases. The company's extensive brand resources and operational experience will complement Lianshi's advanced AI tools and deep collaboration with Alibaba [1][2] 2. **Rapid Growth in AI Vertical Application Revenue** A significant performance inflection point is anticipated in 2025, with an expected revenue growth of approximately 50%. Key drivers include: - Use of AI tools to enhance gross margins and profitability for existing brands - Contributions from new brands such as Colgate, Watsons, Burberry Beauty, and Bawang Tea - Rapid revenue growth from AI vertical applications, with an estimated increase of about 20 million in revenue across various AI verticals in the second half of 2025 - Improvements in operational management quality and cost reduction [3] 3. **Diversified Layout for 2026 Including Robotics and AI** The company aims to maintain its growth momentum into 2025, focusing on light asset operations to enhance gross margins. Key initiatives include the rollout of three major AI products: customer service, image generation, and promotion. New contracts with vertical clients like Disney and Walmart signed in the fourth quarter of 2025 are expected to drive revenue growth. The AI segment plans to establish a separate financial model and explore partnerships in emerging categories like brain-computer interfaces and robotics [4] 4. **Deepening Brain-Computer Interface Cooperation for Diverse Brand Services** A partnership with a leading brain-computer interface company in Hangzhou has commenced, with plans for further expansion in 2026. The company aims to leverage its fast-moving consumer goods (FMCG) to consumer (B2C) operational experience to address the partner's shortcomings in consumer insights. The goal is to diversify brand services through online collaborations with emerging AI companies [4] 5. **Enhancing Douyin Content Capabilities to Solidify Alibaba Collaboration** In 2026, the company will focus on strengthening its content generation capabilities on Douyin, with ongoing discussions for related collaborations. The number of vertical co-creation partners with Alibaba has been reduced from 10 to 4, yet the company's ranking among the remaining partners remains strong, with no change in collaboration share despite the reduction [5]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][53]. Core Viewpoints - The report emphasizes the strong logic behind the innovative drug industry, suggesting that the stock prices have adjusted sufficiently, making current investments relatively cost-effective. It recommends focusing on stocks with high or certain returns, particularly those expected to perform well in Q1 [5][42]. - The report highlights the rapid growth of balloon-expandable valves (BEV) in TAVR procedures, with a projected increase in the number of procedures in China, reaching over 18,000 by 2025, representing an 8.1% year-on-year growth. The proportion of BEV usage is expected to rise significantly [8][16]. - The report outlines a dual investment framework focusing on "technology innovation leadership" and "performance/valuation recovery" for the year [23][43]. Summary by Sections 1. TAVR Procedure Growth - The number of TAVR procedures in mainland China is expected to exceed 18,000 by 2025, with a year-on-year growth of 8.1%. The proportion of balloon-expandable valves is projected to increase from 7.5% in 2024 to 13% in 2025 [8][16]. 2. Industry Performance Analysis - From March 2 to March 6, the pharmaceutical index fell by 2.78%, underperforming the CSI 300 index by 1.71%. Despite this, innovative drugs showed a significant rebound, with stocks like Yahu Medicine rising over 38% [5][23]. - The report lists several stocks to watch, including innovative drug companies and those with stable growth or potential for performance reversal [5][42]. 3. Investment Recommendations - The report suggests focusing on innovative drugs, AI medical technology, and surgical robots as key areas for investment in 2026. Specific companies highlighted include Heng Rui Medicine, Xin Li Tai, and Bai Ren Medical [5][42][45]. - It also emphasizes the importance of the aging population and outpatient consumption as growth drivers, recommending companies like Kun Yao Group and Yu Yao Medical [45]. 4. Market Trends and Valuation - The overall PE valuation for the pharmaceutical sector is 36.18x, indicating that the sector remains at a relatively low historical valuation. The report notes that various sub-sectors have differing valuation levels, with some being relatively high [31][42].

Investment Rating - The report maintains an "Increase" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector has experienced a decline of 2.78% this week, ranking 17th out of 31 sectors, while it has seen a slight increase of 0.1% year-to-date, ranking 24th out of 31 [9] - The 2026 government work report emphasizes the importance of the biopharmaceutical industry, categorizing it as a "new pillar industry," which indicates a strategic upgrade in its significance for economic growth and industrial upgrading [10][11] - The inclusion of brain-computer interfaces in the government work report marks a significant policy shift, enhancing market focus on related fields such as neural regulation and rehabilitation robotics [11] Company Dynamics - China Biopharmaceutical has entered an exclusive licensing agreement with Sanofi for the innovative drug Roflumilast, potentially earning up to $1.53 billion, including an upfront payment of $135 million [12] - Deking Pharmaceuticals has secured a global exclusive licensing agreement for ATG-201 with UCB, which includes an upfront payment of $80 million and potential milestone payments totaling approximately $1.1 billion [13] - East China Pharmaceutical has received approval to conduct clinical trials for DR30206, a fusion protein targeting multiple pathways for non-small cell lung cancer [14] - Yahui Pharmaceutical has achieved a commercial breakthrough with the approval of APL-1702 for treating cervical intraepithelial neoplasia [15] Investment Focus - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector as key investment opportunities [4][16]

Market Overview - Major indices showed positive performance with the ChiNext Index up by 0.38%, the Shenzhen Component Index up by 0.59%, and the STAR Market 50 Index up by 0.64% [1] - The TMT sector led the gains, with the SW Brand Consumer Electronics rising by 4.04% and SW Other Electronics III increasing by 2.45% [1] - Conversely, the TMT sector also saw declines, with SW Communication Cables and Supporting down by 4.37% and SW Integrated Circuit Packaging and Testing down by 2.21% [1] Domestic News - Media reports that MediaTek showcased its first AI smart glasses prototype, powered by the flagship mobile platform Dimensity 9500, emphasizing local computing capabilities and user privacy [1] - Jiangbolong disclosed core advancements in its main control chip and innovative mSSD products, indicating that its flagship products are nearing mass shipment [1] - Huawei launched the Atlas 950 SuperPoD intelligent computing node, which supports up to 8192 NPU cards, significantly enhancing training efficiency and reliability compared to Nvidia [1] - BYD announced the second-generation blade battery and fast-charging technology, capable of charging in 5 minutes and establishing 20,000 fast-charging stations by the end of 2026 [1] Overseas News - Marvell reported FY26 revenue of $8.195 billion, with expectations for accelerated revenue growth in FY27 driven by strong data center business performance [2] - Denso has made a public tender offer to acquire all shares of Rohm for approximately 1.3 trillion yen (about 63 billion RMB), aiming to enhance competitiveness in power semiconductors for electric vehicles [2] - The U.S. government is drafting new export control regulations that will require approval for the export of advanced AI accelerators produced by U.S. companies [2] - Samsung secured a contract to provide 5G Open RAN RF equipment to Rakuten Mobile in Japan, covering a range of frequency bands [2] AI News - OpenAI launched GPT-5.4, the first general model with native computer usage capabilities, achieving a success rate of 75% in OSWorld-Verified tests [3] - Google DeepMind introduced the AI programming agent AlphaEvolve, which can generate and iterate programs, achieving optimal solutions in 50+ tests [3] - Alibaba Cloud released HiClaw, an upgraded version of OpenClaw, focusing on multi-agent collaboration management [3] - VAST AI completed a $50 million Series A funding round, with plans to invest in world model development and UGC interactive content platform construction [3] Industry Tracking - SpaceX plans to launch approximately 1,200 second-generation satellites by the end of 2027 to provide mobile Starlink internet services with download speeds of up to 100 Mbps [4] - Cheng Tian Technology completed a B+ round financing, focusing on expanding the market for consumer-grade exoskeletons and brain-machine interface products [4] - The Ministry of Industry and Information Technology stated that China's AI core industry scale will exceed 1.2 trillion RMB by 2025, with over 300 humanoid robot products released [4] - The Dejing high-quality stainless steel pipe project has partially commenced production, with 23 production lines operating efficiently [4]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector has experienced a decline of 2.78% this week, ranking 17th out of 31 sectors, with a year-to-date increase of 0.1%, ranking 24th out of 31 [9] - The 2026 government work report emphasizes the importance of the biopharmaceutical industry, positioning it as a key pillar for economic growth and industrial upgrading, particularly highlighting the innovative drug sector as a core beneficiary [10][11] - The inclusion of brain-computer interfaces in the government work report marks a significant policy shift, elevating the field to a national industrial support framework, which is expected to enhance market focus on related technologies [11] Company Dynamics - China Biopharmaceutical has entered an exclusive licensing agreement with Sanofi for the innovative drug Roflumilast, with potential payments totaling up to $1.53 billion, including an upfront payment of $135 million [12] - Deking Pharmaceuticals has reached a global exclusive licensing agreement with UCB for ATG-201, with an upfront payment of $80 million and potential milestone payments totaling approximately $1.1 billion [13] - East China Pharmaceutical has received approval to conduct clinical trials for DR30206, a targeted therapy for non-small cell lung cancer [14] - Yahui Pharmaceutical has obtained approval for APL-1702, a product aimed at treating cervical intraepithelial neoplasia [15] Suggested Focus Areas - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector as key investment opportunities [4][16]

Market Overview - The Shanghai Composite Index decreased by 0.44%, while the North Exchange A-share Index fell by 3.95%, underperforming the Shanghai Composite by 3.52 percentage points[12] - The North Exchange 50 Index dropped by 6.57%, lagging behind the Shanghai Composite by 6.13 percentage points[12] - The average daily trading volume for North Exchange A-shares was 236.87 billion CNY, up 31.9% compared to the previous period[14] Liquidity and Valuation - The total trading volume for North Exchange A-shares was 1184.36 billion CNY, with the North Exchange 50 accounting for 30.29% of this total[14] - As of March 6, 2026, the median price-to-earnings (PE) ratio for North Exchange A-shares was 45.03X, compared to 37.34X for the Sci-Tech Innovation Board and 37.39X for the ChiNext Board[14] Individual Stock Performance - As of March 6, 2026, there were 297 companies listed on the North Exchange, with notable gainers including Teris, Keli Co., and Changjiang Energy Technology[18] - The top two newly listed companies this week, Tongling Technology and Haifiman, saw first-day gains of 41.42% and 170.42%, respectively[20] Industry Dynamics - The government work report emphasized the development of emerging industries such as aerospace, artificial intelligence, and quantum technology, marking a significant policy shift[3] - The Ministry of Industry and Information Technology announced plans to promote AI and manufacturing integration, targeting advancements in AI products and technologies[3] Investment Recommendations - Investors are advised to focus on companies with core technological advantages and stable performance, particularly in robotics, new energy, and commercial aerospace sectors[8] - The North Exchange is expected to attract more capital as its index system improves, making it a favorable environment for investment in fundamentally sound companies[8] Risk Factors - Potential risks include lower-than-expected market demand, intensified industry competition, geopolitical risks, and delays in policy implementation and R&D progress[9]